Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
Announces senior leadership appointments to further support client programs and growing sales pipelineDURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) --...
Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected...
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust...
Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE...
Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more...
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety...
DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered...
Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish...
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer...
Issues 2024 financial guidanceWARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a...
Robert M. Brenner Robert M. Brenner, M.D., Chief Medical Officer William D. Turner William D. Turner, Chief Development Officer BRISBANE,...
Company provides year-end health plan membership guidance, strengthens conviction of path to adjusted EBITDA breakeven in 2024ORANGE, Calif., Jan. 08,...
First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of...
“Life Couriers acquires RLG to create the global logistic leader for radiopharmaceuticals transportation”. Philippe Sueur, Isovital President stated: « Significant efforts were...
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024...
Portage, Michigan, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it surpassed $20 billion in annual sales...
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader...
Six Presentations Highlight Landos’ Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative ColitisNEW...